Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Reduced by FourThought Financial Partners LLC

FourThought Financial Partners LLC cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 24.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,231 shares of the life sciences company’s stock after selling 5,589 shares during the period. FourThought Financial Partners LLC’s holdings in Illumina were worth $2,399,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ILMN. Vanguard Group Inc. grew its position in Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock worth $2,466,614,000 after acquiring an additional 2,336,935 shares in the last quarter. Barclays PLC raised its holdings in Illumina by 120.0% during the third quarter. Barclays PLC now owns 1,768,355 shares of the life sciences company’s stock valued at $242,758,000 after buying an additional 964,709 shares in the last quarter. abrdn plc lifted its position in shares of Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after buying an additional 299,827 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Illumina by 245.7% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 417,876 shares of the life sciences company’s stock valued at $57,366,000 after acquiring an additional 296,990 shares during the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of Illumina in the 3rd quarter valued at approximately $29,558,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 4.9 %

Shares of NASDAQ ILMN traded down $6.06 during mid-day trading on Friday, hitting $117.93. The company’s stock had a trading volume of 2,987,105 shares, compared to its average volume of 1,375,095. The company’s fifty day simple moving average is $130.03 and its 200-day simple moving average is $127.02. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. Illumina, Inc. has a one year low of $89.00 and a one year high of $213.91. The stock has a market cap of $18.78 billion, a price-to-earnings ratio of -14.47 and a beta of 1.20.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.28%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the business earned $0.08 EPS. The firm’s revenue was down 1.0% on a year-over-year basis. On average, sell-side analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. HSBC cut Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Barclays raised their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Illumina in a research note on Wednesday, April 10th. Finally, Robert W. Baird lifted their price objective on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $165.10.

Insider Transactions at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 0.17% of the stock is owned by insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.